Related Experiment Videos

Optimal use of beta-blockers in high-risk hypertension: a guide to dosing equivalence

Janet B McGill1

  • 1Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA. jmcgill@im.wustl.edu

Vascular Health and Risk Management
|June 12, 2010
PubMed

Insights

Primary care physicians can improve hypertension management by selecting appropriate antihypertensive agents. Beta-blockers offer benefits for high-risk patients, especially those with diabetes, when used with evidence-based protocols.

Area of Science:

  • Cardiology
  • Pharmacology
  • Primary Care Medicine

Background:

  • Hypertension is a leading diagnosis in primary care, necessitating individualized antihypertensive treatment.
  • Elevated blood pressure (BP > 130/80 mmHg) in diabetic patients significantly increases cardiovascular and renal risks.
  • Beta-blockers are increasingly vital for managing hypertension in high-risk populations.

Purpose of the Study:

  • To review the heterogeneity of beta-blocker agents.
  • To provide evidence-based protocols for selecting optimal beta-blocker regimens.
  • To address dose equivalence for complex patient needs.

Main Methods:

  • Review of existing literature on beta-blocker pharmacology and clinical trials.
  • Analysis of evidence-based protocols for hypertension management.
  • Assessment of factors influencing long-term medication adherence.

Main Results:

  • Beta-blockers represent a diverse class of antihypertensive drugs.
  • Understanding dose equivalence is crucial for regimen selection in complex patients.
  • Long-term adherence is key to realizing the clinical benefits of beta-blockers.

Conclusions:

  • Beta-blockers with proven efficacy, once-daily dosing, and favorable side effect profiles are valuable.
  • These agents can be instrumental in treating both diabetic and non-diabetic hypertensive patients.
  • Personalized selection of beta-blockers supports effective hypertension management.

Keywords:
antihypertensiveatenololblood pressurecarvedilollabetalolmetoprololnebivolol

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...